Combination Nicotine Replacement for Alcoholic Smokers
NCT00064844 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 96
Last updated 2021-08-13
Summary
The overall objective of the study is to develop recommendations for treatment programs to help alcoholic smokers to stop smoking. A sample of 175 alcohol dependent cigarette smokers will be recruited from the community and treated in a 6-month outpatient alcohol and tobacco treatment program. The 175 patients will be divided into two groups. One group will receive an active nicotine patch and active nicotine gum. The other group will receive an active nicotine patch and placebo nicotine gum. Followup assessments will be conducted for 1-year from the beginning of treatment.
Conditions
- Smoking
- Alcoholism
Interventions
- BEHAVIORAL
-
Cognitive Behavior Therapy for alcohol and smoking cessation
Individual 60-minute treatment sessions were scheduled weekly for the first 3 months, then monthly for the next 3 months for a total of 16 sessions. Alcohol treatment was based on the cognitive behavioral therapy manual developed for Project MATCH, with approximately 40-45 minutes of each session devoted to alcohol treatment. Components of this intervention included identifying alcohol antecedents, coping with alcohol urges, managing thoughts about alcohol, problem solving, drink refusal skills, planning for emergencies, communication and assertiveness training and enhancing social support networks for alcohol abstinence. The smoking cessation intervention was delivered in the same sessions as the alcohol treatment, with approximately 15-20 minutes of each session devoted to smoking cessation. Treatment employed behavioral elements that have been supported empirically according to the USDHHS smoking cessation practice guideline.
- DRUG
-
Nicoderm CQ nicotine patch
Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy.
- DRUG
-
Placebo gum
Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
- DRUG
-
Nicotine gum - Nicorette®
Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.
Sponsors & Collaborators
-
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
collaborator NIH -
Yale University
lead OTHER
Principal Investigators
-
Ned Cooney, PhD · Yale University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-08-31
- Primary Completion
- 2006-07-31
- Completion
- 2006-07-31
Countries
- United States
Study Locations
More Related Trials
-
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
NCT00342563 ·Status: COMPLETED ·Phase: PHASE2
-
Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use
NCT02870218 ·Status: COMPLETED ·Phase: PHASE2
-
Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation
NCT02859142 ·Status: COMPLETED ·Phase: PHASE4
-
Combination Nicotine Patch / Lorcaserin for Smoking Cessation
NCT02906644 ·Status: COMPLETED ·Phase: PHASE2
-
Nicotine Withdrawal Symptoms and Smoking Relapse
NCT01511614 ·Status: COMPLETED ·Phase: NA
-
New Approaches to Smoking Cessation in Heavy Drinkers
NCT02151591 ·Status: COMPLETED ·Phase: PHASE1
-
Combination of Nicotine Replacement Therapy (NRT) and Varenicline to Increase Cessation of Tobacco (CONVICT Study)
NCT01184664 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Varenicline on Reactivity to Smoking and Drinking Cues
NCT00873535 ·Status: COMPLETED ·Phase: NA
-
Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers
NCT01048944 ·Status: COMPLETED ·Phase: PHASE4
-
Non-Nicotine Agents for Smoking Cessation
NCT00108537 ·Status: COMPLETED ·Phase: PHASE3
-
A Pilot Clinical Trial of Varenicline as a Treatment for Alcohol Dependence
NCT01011907 ·Status: COMPLETED ·Phase: NA
-
The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence
NCT02590393 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Reduced Nicotine Cigarettes in Smokers With and Without Alcohol Use Disorder
NCT02990455 ·Status: COMPLETED ·Phase: PHASE1
-
Interactive Psychopharmacologic Effects of Alcohol and Nicotine in Humans
NCT00616746 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Varenicline For Smokers In Recovery From Alcohol Dependence
NCT01092702 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Sensorimotor Replacement With Electronic and De-nicotinised Cigarettes
NCT01414998 ·Status: COMPLETED ·Phase: NA
-
Varenicline in Drug Treatment
NCT01286584 ·Status: COMPLETED ·Phase: PHASE4
-
Varenicline Treatment for Active Alcoholic Smokers
NCT01347112 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Treatment to Quit Smoking
NCT00018161 ·Status: COMPLETED ·Phase: PHASE2
-
Adaptive Pharmacotherapy for Smoking Cessation
NCT02501265 ·Status: COMPLETED ·Phase: PHASE2
-
Nicotine Replacement Therapy in Nicotine-dependent Arrestees
NCT02905734 ·Status: COMPLETED ·Phase: PHASE4
-
Extinction Based Treatment for Nicotine Dependence
NCT00831155 ·Status: COMPLETED ·Phase: PHASE1
-
Combining Varenicline and Naltrexone for Smoking Cessation
NCT02698215 ·Status: COMPLETED ·Phase: PHASE2
-
Cytisine Compared to Combination NRT in Relapsed Smokers
NCT04286295 ·Status: TERMINATED ·Phase: NA
-
Varenicline and Alcohol in Inpatient Addictions Program (IAP)
NCT01169610 ·Status: TERMINATED ·Phase: PHASE3